Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting

AIDS

Volumn 25, Issue 12, 2011, Pages 1471-1479

  Wester, C William ^a,b,c,d   Koethe, John R ^a   Shepherd, Bryan E ^a   Stinnette, Samuel E ^a   Rebeiro, Peter F ^a   Kipp, Aaron M ^a,d   Hong, Hwanhee ^b   Bussmann, Hermann ^b,c   Gaolathe, Tendani ^c   McGowan, Catherine C ^a   Sterling, Timothy R ^a   Marlink, Richard G ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

combination antiretroviral therapy; HIV AIDS; non AIDS defining events; urban sub Saharan Africa; urban United States

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BOTSWANA; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; UNITED STATES; URBAN AREA;

ADULT; ANTI-RETROVIRAL AGENTS; BOTSWANA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TENNESSEE; URBAN HEALTH; VIRAL LOAD; VIRUS REPLICATION;

EID: 79960562235     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328347f9d4     Document Type: Article

References (41)

1. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19; Epub 2006 June 1. PMID: 16741877.
2. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquired Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
3. The Antiretroviral Therapy Cohort Collaboration (ART-CC writing committee). Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
4. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related mortality. BMJ 2009; 338:a3172.
5. Martinez E, Milinkovic A, Buira E, de Lazzari E, Leon A, Larrousse M, et al. Incidence and causes of death in HIVinfected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007; 8:251-258. (Pubitemid 46695372)
6. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 2010; 24:789-802.
7. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70. (Pubitemid 43063843)
8. Kuller LH, Tracy R, Belloso W, deWit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203; doi:10.1371/journal.pmed.0050203.
9. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-näve subjects before and after starting potent antiretroviral therapy. J Am Coll Cardiol 2008; Vol.52:569-576.
10. DAD Study group; Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735. (Pubitemid 46658704)
11. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-1631. (Pubitemid 46871511)
12. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency disease. J Clin Endocrinol Metab 2007; 92:2506-2512. (Pubitemid 47037350)
13. Currier JS. Cardiovascular risk associated with HIV therapy. J Acquir Immune Defic Syndr 2002; 31 (Suppl 1):S16-23; discussion S4-5.
14. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-1631. (Pubitemid 46871511)
15. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23:41-50.
16. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, Mocroft A, for the INSIGHT SMART and ESPRIT study groups. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697-706.
17. Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, Gaolathe T, et al. Nonnucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS 2010; 24 (Suppl 1):S27-S36.
18. Botswana Guidelines on Antiretroviral Treatment, 2002 version. 2002, Ministry of Health, Botswana: Gaborone, Botswana.
19. Botswana Guidelines on Antiretroviral Treatment. 2005 version. 2005, Ministry of Health, Botswana: Gaborone, Botswana.
20. Division of AIDS, NIAID. Division of AIDS Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 1994.
21. Division of AIDS, NIAID. Division of AIDS Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; December 2004.
22. Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, et al. Estimating the optimal CD4 count for HIVinfected patients to start antiretroviral therapy. Epidemiology 2010; 21:698-705.
23. Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Velloso VG, et al. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med 2010; 11:554-564.
24. Kao WHL, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, et al. A genome-wide admixture scan identifies MYH9 as a candidate locus associated with nondiabetic end stage renal disease in African Americans. Nat Genet 2008; 40:1185-1192.
25. Winkler CA, Nelson GW, Oleksyk TK, Nava MB, Kopp JB. Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation. Semin Nephrol 2010; 30:111-125.
26. Freedman BI, Hicks PJ, Bostrom MA, Comeau ME, Divers J, Bleyer AJ, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009; 75:736-745.
27. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIVassociated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42:1488-1495.
28. Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis 2008; 46:1282-1289. (Pubitemid 351589915)
29. Kauffman L, Collins SE, Klotman PE. The pathogenesis of HIVassociated nephropathy. Adv Chronic Kidney Dis 2010; 17:36-43.
30. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al. Baseline renal insufficiency and risk of death among HIVinfected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 2008; 22:1821-1827.
31. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol 2009; 50:655-658.
32. Rosenthal E, Samon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med 2009; 10:282-289; Epub 2009 Feb 15.
33. Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIVinfected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:447-450.
34. Wester CW, Bussmann H, Moyo S, Avalos A, Gaolathe T, Ndwapi N, et al. Serological evidence for HIV-associated infections among HIV-1C infected adults in Botswana. Clin Infect Dis 2006; 43:1612-1615. (Pubitemid 44901905)
35. Adewole OO, Anteyi E, Ajuwon Z, Wada I, Elegba F, Ahmed P, et al. Hepatitis B and C virus co-infection in Nigerian patients with HIV infection. J Infect Dev Ctries 2009; 3:369-375.
36. Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, Penugonda S, et al. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected adults. Ann Hepatol 2008; 7:152-156. (Pubitemid 351845527)
37. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67. (Pubitemid 47017468)
38. Weverling GJ, Lange JM, Jurriaans S, Prins JM, Lukashov VV, Notermans DW, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998; 12:F117-F122. (Pubitemid 28330714)
39. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-1765. (Pubitemid 33153000)
40. Ghani AC, Ferguson NM, Fraser C, Donnelly CA, Danner S, Reiss P, et al. Viral replication under combination antiretroviral therapy: a comparison of four different regimens. Acquir Immune Defic Syndr 2002; 30:167-176. (Pubitemid 34664413)
41. Maggiolo F, Migliorino M, Pirali A, Pravettoni G, Caprioli S, Suter F. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000; 25:36-43.